Eyal Kalo, Ph.D.

Affiliations: 
2009 MCB Molecular Cell Biology Weizmann Institute of Science, Rehovot, Israel 
Area:
Molecular Biology, Genetics, Oncology
Google:
"Eyal Kalo"

Parents

Sign in to add mentor
Varda Rotter grad student 2009 Weizmann Institute
 (The Molecular mechanism underlying mutant p53 gain of function in both TGF-beta and Nrf2 pathways.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kalo E, Kogan-Sakin I, Solomon H, et al. (2012) Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. Journal of Cell Science. 125: 5578-86
Solomon H, Buganim Y, Kogan-Sakin I, et al. (2012) Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. Journal of Cell Science. 125: 3144-52
Buganimy Y, Madary S, Rais Y, et al. (2011) Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression Carcinogenesis. 32: 1749-1757
Buganim Y, Goldstein I, Lipson D, et al. (2010) A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. Plos One. 5: e9657
Stambolsky P, Tabach Y, Fontemaggi G, et al. (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 17: 273-85
Buganim Y, Solomon H, Rais Y, et al. (2010) p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Research. 70: 2274-84
Stambolsky P, Tabach Y, Fontemaggi G, et al. (2010) Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53 (DOI:10.1016/j.ccr.2009.11.025) Cancer Cell. 17: 523
Kalo E, Buganim Y, Shapira KE, et al. (2007) Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Molecular and Cellular Biology. 27: 8228-42
Milyavsky M, Shats I, Cholostoy A, et al. (2007) Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell. 11: 133-46
Buganim Y, Kalo E, Brosh R, et al. (2006) Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Research. 66: 10750-9
See more...